Novo Nordisk A/S scrapped a partnership with Hims & Hers Health Inc. after less than two months, saying the US company is ...

GPs in England are now allowed to prescribe Mounjaro to severely obese people who also suffer from a range of other health ...

The combination offers a potential solution to one of the key problems that’s emerged with popular obesity shots.

Mounjaro offers up to 20% weight loss – but it’s not for everyone. Learn about eligibility, alternatives and why long-term ...

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...

Hims & Hers stock plunged around 30% on Monday after drugmaker Novo Nordisk abruptly ended a month-long collaboration to make ...

The Wegovy maker says the telehealth company didn't stop selling compounded versions of the blockbuster drug after Novo ...

While Eli Lilly brushed off concerns about gastrointestinal side effects for oral weight loss candidate orforglipron, ...

A new potential drug treatment for people with type 2 diabetes and obesity lowers blood sugar and increases fat burning.

Lower blood sugar and increased fat burning—without negatively affecting appetite or muscle mass. These are some of the most ...

A new weight loss pill currently undergoing clinical trials could help burn fat and lower blood sugar levels like Ozempic and ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...